Better Quantum Stock: Rigetti Computing vs. Quantum Computing

Rigetti (RGTI) and Quantum Computing/QCi (QUBT) are contrasted as two speculative plays in quantum computing: Rigetti sells superconducting systems (Ankaa-3 84-qubit, Cepheus-1-36Q 36-qubit) and plans 108‑ and 150+‑qubit systems this year and a 1,000+‑qubit system by end‑2027, while QCi develops photonic chips and only began deliveries last year. Analysts expect Rigetti revenue to rise from $7.6M in 2025 to $45.4M in 2027 (implying ~160x 2027 sales vs. its $7.3B market cap) and QCi revenue to increase from ~$0.8M this year to $15M in 2027 (implying ~166x 2027 sales vs. $2.5B market cap); both companies are expected to remain unprofitable. The author prefers Rigetti for its established technology and clearer roadmap, while noting QCi’s photonic approach is potentially disruptive but faces manufacturing and scaling hurdles.

Analysis

Market structure: Rigetti (RGTI) benefits if customers prefer a full-stack provider and if its cloud services (Forest) convert to recurring revenue; hyperscalers and gov agencies are likely buyers, supporting premium multiples despite tiny current revenue (RGTI market cap ~$7.3bn = ~160x 2027 sales). QCi (QUBT) faces fabrication scaling and gate-fidelity hurdles; if photonics remain uneconomic at small volumes, incumbent superconducting suppliers keep pricing power. Cryogenics supply (helium) and silicon-photonics fab capacity create asymmetric supply constraints that favor well-capitalized players in the near term.

Risk assessment: Tail risks include technology dead-ends (photonic gate-fidelity shortfall), sudden contract losses (another NQI-style expiration), and rapid dilution if capital markets tighten; each could cut implied valuations >50% within 12 months. Immediate (days) volatility will track press releases and funding headlines; short-term (months) hinge on reported system deployments (108q/150+ launches H2 2026); long-term (2027+) depends on commercial revenue scale and hyperscaler adoption. Hidden dependencies: wafer fab partnerships, IP litigation, and integration with cloud providers are second-order determinants of survivorship.

Trade implications: Favor asymmetry — small directional exposure to RGTI’s execution with downside protection, and selective short/put exposure to QUBT until manufacturing proof points arrive. Use pair trades to neutralize macro beta (long RGTI / short QUBT ~2:1) and harvest premium via short near-term calls funded by long-dated calls or stock. Rotate capital from micro-cap quantum names into large-cap semis/AI (NVDA or SOXX) to capture real semi/AI secular demand while lowering idiosyncratic risk.

Contrarian angles: The market underprices recurring cloud revenue optionality — if Rigetti books multi-year cloud contracts, a re-rating could be swift even with modest revenue (doubling ARR could rerate multiples given scarcity of full-stack providers). Conversely, consensus underestimates the binary upside of QUBT: successful photonic scaling could produce >5x sales growth vs current forecasts, so outright shorting without strict catalysts is a high-risk, high-reward call. Historical parallel: early GPU makers were binary until hyperscalers standardized on a small number of vendors; quantum could consolidate similarly, favoring well-capitalized incumbents.

Key Decisions for Investors

• Establish a 1.5% portfolio long position in RGTI now (equity or 18-month LEAP calls) and scale to 3% only if: a) Rigetti confirms deployment of the 108-qubit or 150+ system within stated H2–2026 timeline, or b) 2026 revenue guidance moves toward >$20m. Place a hard stop at -35% from entry or hedge with 9–12 month protective puts if drawdown hits -20%.
• Initiate a tactical 0.5% short position in QUBT via equity or a 12-month put spread (limit cost) with a monitoring trigger: increase to 1.5% if QCi fails to show meaningful chip production or cloud adoption by Sept 30, 2026, or if 2026 revenue guidance stays < $5m. Target asymmetric payoff of 50–70% downside on catalyst misses.
• Run a pair trade: long RGTI (1.5%) / short QUBT (0.75%) to exploit execution gap; rebalance on material catalysts (Rigetti system deployment or QCi fabrication milestones). Close or reduce positions 30–60 days after catalyst confirmation or failure.
• Reduce speculative quantum micro-cap exposure by 2–4% and redeploy into large-cap semiconductors (e.g., NVDA or SOXX) to capture durable AI/semiconductor demand; hold 6–18 months and reassess after major earnings or government contract cycles.